Fusion Rx Compounding Pharmacy: The Pharmacy Paid the Patient’s Share

The Fusion Rx compounding case involved approximately $14 million in reimbursements from May 2014 to at least February 2016 for prescriptions generated through referral kickbacks and false patient copayments, according to the Justice Department’s account of the criminal guilty pleas. The West Los Angeles pharmacy used its own money to make payments that it represented to insurers as coming from patients. If you handled prescription intake, marketing payments or copay reconciliation, you may recognize the gap between the payment on the screen and the person who actually funded it.

What Fusion Rx Admitted in Its Guilty Plea

In their guilty plea agreements, Fusion Rx and its owner admitted routing millions of dollars in kickbacks through the businesses of two marketers to steer compounded-drug prescriptions to the pharmacy.

The business supplied compounded drugs, tailor-made products doctors may prescribe when an FDA-approved alternative does not meet a patient’s health needs. Yet the people generating prescriptions also supplied the forms designed to maximize what insurers would pay.

The Defense Criminal Investigative Service, the FBI, the Amtrak Office of Inspector General, the Office of Personnel Management’s Office of Inspector General and the Office of Inspector General for the United States Department of Health and Human Services investigated the Fusion case.

Prescription Pads Built Around Reimbursement

The criminal plea announcement describes preprinted prescription pads with checkbox options designed to maximize insurance reimbursement. The owner and the two marketers provided the pads to physicians.

The pad put the reimbursement strategy in front of the prescriber before the pharmacy submitted a claim. It belonged in the same story as the referral payment: one steered prescriptions to the pharmacy, while the other shaped the options offered to the physician.

This is a recurring feature of compounding pharmacy fraud: the commercial incentive can reach back into how a prescription is generated. Here, the government’s account ties the form’s design directly to insurance reimbursement. We see a reimbursement strategy dressed up as individualized medicine. The patient’s needs were supposed to be the starting point.

For someone who worked with those forms, the detail may be who supplied the pad or explained the choices on it. A billing employee may see the resulting prescription without seeing the marketing arrangement that brought it in. We connect those views when examining how the prescription became a claim.

Copayments Funded With Pharmacy Money

The Justice Department’s guilty-plea announcement describes the copayment scheme from criminal court documents. Fusion Rx’s insurance-network contracts required it to collect patient copayments, but the pharmacy did not collect them regularly because the payments might discourage patients from requesting expensive and potentially unnecessary compounded prescriptions. In other instances, it gave patients gift cards to offset their copayments.

Then came an audit. According to the announcement’s account of those court documents, the audit raised concerns that the failure to collect copayments would be discovered. The owner directed pharmacy funds toward purchases of American Express gift cards. Those cards were used to make copayments for certain prescriptions without the patients’ knowledge.

Fusion Rx submitted claims on those prescriptions to insurers and falsely represented that patients had paid the required copayments.

The pharmacy funded the patient’s side of the transaction, then used the apparent patient payment to support its own insurance claim. Paid, on paper.

That is why the source of the copayment matters. A receipt showing a completed transaction would miss the central fact if it did not show whose money bought the card. The purchase instruction, the pharmacy’s expenditure and the payment applied to the prescription explain what the claim concealed. The patient’s lack of knowledge also matters: the government described payments made in patients’ names without their participation.

What the Payment Entry Concealed

The useful question in Fusion Rx is what the pharmacy told the insurer had happened, and what actually happened to the money. Someone reconciling copayments could see a completed payment while the purchase instruction showed the pharmacy had funded it. That is the connection we examine with an insider who knows how the payments were handled.

The usual and customary price reported to a payer raises a different question: which public cash price the pharmacy represented. With claims for uncollected prescriptions, the question is whether the patient received the drug. Fusion’s gift-card arrangement puts the focus on who supplied the money. The claim’s representation and the transaction behind it have to be examined together.

Where the Same Incentives Appeared in Civil Cases

Patient Care America shows how disguised copayment funding can also appear in a civil False Claims Act case. In its September 2019 civil settlement announcement, the Justice Department alleged that the pharmacy paid marketers targeting military families, financed physician referrals, selected high-reimbursement compounds and disguised copayment funding through a charity associated with a marketer. Patient Care America and private-equity firm Riordan, Lewis & Haden agreed to a joint $21.05 million civil payment.

The alleged charity arrangement put another organization between the pharmacy and the apparent assistance. Fusion’s criminal case described gift cards bought with pharmacy money. In each account, following the funding explains something a patient-payment entry alone would leave out.

The whistleblowers in the Patient Care America case worked in marketing and reimbursement. Their roles illustrate why the employee who understands prescription generation and the employee who understands payment may see different parts of the same arrangement.

Fagron’s November 2019 civil resolution shows how the incentive could also enter through an ingredient price. The government alleged that ingredient supplier Freedom reported an average wholesale price of $3,500 per gram for fluticasone while typically selling it for about $160 per gram. That puts the reimbursement benchmark beside the supplier’s selling price, where the gap becomes visible.

These civil allegations show why we examine the businesses supplying referrals, ingredients and payment arrangements alongside the pharmacy submitting the claim. A prescription can carry decisions made well before it reaches the billing screen.

What Can a Pharmacy Fraud Whistleblower Receive?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know Who Funded the Copayment

If you saw pharmacy money turned into apparent patient payments or referral arrangements built around reimbursement, speak to one of our whistleblower experts about who funded those copayments. We build your strongest pharmacy fraud whistleblower case with you and bring in pharmacy fraud whistleblower lawyers who understand compounding claims, referral payments and copay records. We stay beside you through the case, keeping the focus on who paid, who directed it and what the insurer was told.